EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration

Rebecca Sconza iD, Georgina Fernandes iD, Virginia Rasi, Heather Bailey iD, Karoline Aebi-Popp iD, Luminita Ene iD, Marco Floridia iD, Anna Gamell iD, Marta Illán Ramos, Helen Peters, Anna Samarina, Giorgia Dalla Valle und 7 weitere

HIV Medicine · 08.11.2026

DOI: 10.1111/hiv.70359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 08.11.2026. Verfasst von Rebecca Sconza und 18 weiteren Autor:innen. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, University College London, London, UK. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting.

Methods

We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD‐10) and the European Network of population‐based registries for the epidemiological surveillance of congenital anomalies (EUROCAT).

Results

Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live‐born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD‐10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live‐born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively.

Conclusions

Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.

Schlagwörter

Stichwörter der Autor:innen

birth defectsbirth outcomesdrug safetyintegrase strand transfer inhibitorpregnancy

Autor:innen und Institutionen

  • UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
  • UCL Institute for Global Health, University College London, London, UK.
  • Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • "Dr. Victor Babes" Hospital of Infectious and Tropical Diseases, Bucharest, Romania.
  • Istituto Superiore di Sanità, Rome, Italy.
  • Hospital Sant Joan de Déu, Barcelona, Spain.

ORCID-Profile: Rebecca Sconza, Georgina Fernandes, Heather Bailey, Karoline Aebi-Popp, Luminita Ene, Marco Floridia, Anna Gamell, Vani Vannappagari, Claire Thorne

Förderung

  • ViiV Healthcare

Zitieren

APA

Sconza, R., Fernandes, G., Rasi, V., Bailey, H., Aebi-Popp, K., Ene, L., Floridia, M., Gamell, A., Ramos, M. I., Peters, H., Samarina, A., Valle, G. D., Morkunaite, G., Giaquinto, C., Ragone, L., Ruiter, A., Vannappagari, V., Thorne, C., & DOLOMITE‐EPPICC Group (2026). Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration. HIV Medicine. https://doi.org/10.1111/hiv.70359

Vancouver

Sconza R, Fernandes G, Rasi V, Bailey H, Aebi-Popp K, Ene L, et al. Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration. HIV Medicine. 2026. doi:10.1111/hiv.70359

BibTeX
@article{Sconza2026,
  author = {Sconza, Rebecca and Fernandes, Georgina and Rasi, Virginia and Bailey, Heather and Aebi-Popp, Karoline and Ene, Luminita and Floridia, Marco and Gamell, Anna and Ramos, Marta Illán and Peters, Helen and Samarina, Anna and Valle, Giorgia Dalla and Morkunaite, Gabija and Giaquinto, Carlo and Ragone, Leigh and Ruiter, Annemiek de and Vannappagari, Vani and Thorne, Claire and DOLOMITE‐EPPICC Group, DOLOMITE‐EPPICC Group},
  title = {Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70359}
}
Kostenlos starten →